Patents by Inventor Roger A. Rajewski

Roger A. Rajewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN
    Publication number: 20260115157
    Abstract: Pharmaceutical formulations containing acetaminophen and sulfoalkyl ether cyclodextrin are described. The formulation includes acetaminophen; and sulfoalkyl ether cyclodextrin, wherein the molar ratio of sulfoalkyl ether cyclodextrin to acetaminophen is in the range of about 0.01 to about 2. The formulations can be prepared in an injectable form for mitigating or treating fever or alleviating pain in a patient.
    Type: Application
    Filed: December 26, 2025
    Publication date: April 30, 2026
    Inventors: James D. Pipkin, Gerold L. Mosher, Roger A. Rajewski
  • COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME
    Publication number: 20260091073
    Abstract: Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from a toxin, or treating a liver disease.
    Type: Application
    Filed: August 12, 2025
    Publication date: April 2, 2026
    Inventors: James D. Pipkin, Roger A. Rajewski, Beau Mainous
  • Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin
    Patent number: 12527755
    Abstract: Pharmaceutical formulations containing acetaminophen and sulfoalkyl ether cyclodextrin are described. The formulation includes acetaminophen; and sulfoalkyl ether cyclodextrin, wherein the molar ratio of sulfoalkyl ether cyclodextrin to acetaminophen is in the range of about 0.01 to about 2. The formulations can be prepared in an injectable form for mitigating or treating fever or alleviating pain in a patient.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: January 20, 2026
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Gerold L. Mosher, Roger A. Rajewski
  • Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
    Patent number: 12390506
    Abstract: Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from a toxin, or treating a liver disease.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: August 19, 2025
    Assignees: CyDex Pharmaceuticals, Inc., University of Kansas
    Inventors: James D. Pipkin, Roger A. Rajewski, Beau Mainous
  • COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME
    Publication number: 20230233638
    Abstract: Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from a toxin, or treating a liver disease.
    Type: Application
    Filed: June 29, 2022
    Publication date: July 27, 2023
    Inventors: James D. Pipkin, Roger A. Rajewski, Beau Mainous
  • Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
    Patent number: 11382944
    Abstract: Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from a toxin, or treating a liver disease.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: July 12, 2022
    Assignees: CyDex Pharmaceuticals, Inc., University of Kansas
    Inventors: James D. Pipkin, Roger A. Rajewski, Beau Mainous
  • COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME
    Publication number: 20200330539
    Abstract: Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from a toxin, or treating a liver disease.
    Type: Application
    Filed: July 2, 2020
    Publication date: October 22, 2020
    Inventors: James D. Pipkin, Roger A. Rajewski, Beau Mainous
  • Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
    Patent number: 10702568
    Abstract: Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from a toxin, or treating a liver disease.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: July 7, 2020
    Assignees: CyDex Pharmaceuticals, Inc., University of Kansas
    Inventors: James D. Pipkin, Roger A. Rajewski, Beau Mainous
  • FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN
    Publication number: 20190255000
    Abstract: Pharmaceutical formulations containing acetaminophen and sulfoalkyl ether cyclodextrin are described. The formulation includes acetaminophen; and sulfoalkyl ether cyclodextrin, wherein the molar ratio of sulfoalkyl ether cyclodextrin to acetaminophen is in the range of about 0.01 to about 2. The formulations can be prepared in an injectable form for mitigating or treating fever or alleviating pain in a patient.
    Type: Application
    Filed: September 15, 2017
    Publication date: August 22, 2019
    Applicant: CyDex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Gerold L. Mosher, Roger A. Rajewski
  • COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME
    Publication number: 20180133274
    Abstract: Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from a toxin, or treating a liver disease.
    Type: Application
    Filed: March 18, 2016
    Publication date: May 17, 2018
    Inventors: James D. Pipkin, Roger A. Rajewski, Beau Mainous
  • Enalapril compositions
    Patent number: 9968553
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: May 15, 2018
    Assignees: SILVERGATE PHARMACAUTICALS, INC., UNIVERSITY OF KANSAS
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • ENALAPRIL COMPOSITIONS
    Publication number: 20180116954
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 3, 2018
    Inventors: Lian G. RAJEWSKI, Roger A. RAJEWSKI, John L. HASLAM, Kathleen HEPPERT, Michael C. BECKLOFF, Frank SEGRAVE, Robert MAURO, Peter COLABUONO
  • Enalapril compositions
    Patent number: 9855214
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 2, 2018
    Assignees: SILVERGATE PHARMACEUTICALS, INC, UNIVERSITY OF KANSAS
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • ENALAPRIL COMPOSITIONS
    Publication number: 20170181968
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 29, 2017
    Inventors: Lian G. RAJEWSKI, Roger A. RAJEWSKI, John L. HASLAM, Kathleen HEPPERT, Michael C. BECKLOFF, Frank SEGRAVE, Robert MAURO, Peter COLABUONO
  • ENALAPRIL COMPOSITIONS
    Publication number: 20150258027
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: October 2, 2013
    Publication date: September 17, 2015
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Rapidly dissolving pharmaceutical compositions comprising pullulan
    Patent number: 8900629
    Abstract: The present disclosure provides rapidly dissolving oral capsules and films comprising pullulan, a plasticizer, and a dissolution enhancing agent.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 2, 2014
    Assignee: University of Kansas
    Inventors: Roger A. Rajewski, Lian G. Rajewski, John L. Haslam
  • Enalapril compositions
    Patent number: 8778366
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: July 15, 2014
    Assignees: University of Kanasas, Silvergate Pharmaceuticals, Inc.
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Enalapril Compositions
    Publication number: 20140100260
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: June 10, 2013
    Publication date: April 10, 2014
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Enalapril compositions
    Patent number: 8568747
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: October 29, 2013
    Assignees: Silvergate Pharmaceuticals, Inc., University of Kansas
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Seagrave, Robert Mauro, Peter Colabuono
  • RAPIDLY DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULAN
    Publication number: 20130005831
    Abstract: The present disclosure provides rapidly dissolving oral capsules and films comprising pullulan, a plasticizer, and a dissolution enhancing agent.
    Type: Application
    Filed: December 22, 2011
    Publication date: January 3, 2013
    Applicant: UNIVERSITY OF KANSAS
    Inventors: Roger A. Rajewski, Lian G. Rajewski, John L. Haslam